U.S. Markets closed

Teva Pharmaceutical Industries Ltd (TEVA) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Teva Pharmaceutical Industries Ltd (TEVA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces and markets generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines. Teva Pharmaceutical Industries Ltd has a market cap of $19.19 billion; its shares were traded at around $17.98 .


For the last quarter Teva Pharmaceutical Industries Ltd reported a revenue of $4.6 billion, compared with the revenue of $5.4 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $18.9 billion, a decrease of 15.8% from the previous year. For the last five years Teva Pharmaceutical Industries Ltd had an average revenue growth rate of 0.1% a year.

The reported loss per diluted share was $2.35 for the year, an increase of -85.5% from previous year. The Teva Pharmaceutical Industries Ltd had a decent operating margin of 16.76%, compared with the operating margin of 17.93% a year before. The 10-year historical median operating margin of Teva Pharmaceutical Industries Ltd is 21.50%. The profitability rank of the company is 8 (out of 10).

At the end of the fiscal year, Teva Pharmaceutical Industries Ltd has the cash and cash equivalents of $1.8 billion, compared with $963.0 million in the previous year. The long term debt was $26.7 billion, compared with $28.8 billion in the previous year. The interest coverage to the debt is 3.3. Teva Pharmaceutical Industries Ltd has a financial strength rank of 4 (out of 10).

At the current stock price of $17.98, Teva Pharmaceutical Industries Ltd is traded at 99.8% discount to its historical median P/S valuation band of $10415.19. The P/S ratio of the stock is 0.00, while the historical median P/S ratio is 2.31. The stock lost 13.6% during the past 12 months.

Directors and Officers Recent Trades:

  • Exec. VP Chief Legal Officer David Matthew Stark sold 3,926 shares of TEVA stock on 02/14/2019 at the average price of $17.74. The price of the stock has increased by 1.35% since.
  • Executive VP, Global R&D Hafrun Fridriksdottir sold 1,841 shares of TEVA stock on 02/14/2019 at the average price of $17.67. The price of the stock has increased by 1.75% since.
  • Executive VP Global Operations Notaristefani Carlo De sold 3,192 shares of TEVA stock on 02/14/2019 at the average price of $17.67. The price of the stock has increased by 1.75% since.
  • Executive VP Global Operations Notaristefani Carlo De sold 5,041 shares of TEVA stock on 02/13/2019 at the average price of $17.88. The price of the stock has increased by 0.56% since.

For the complete 20-year historical financial data of TEVA, click here.

This article first appeared on GuruFocus.